RxDoctor Payments Data

Sarah Hilding, MD

Family Medicine · Hebron, CTNPI 1821382961

Payments from drug & device makers

$1,165in general payments, 2019–2025

Across 34 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$292
  • Novo Nordisk$268
  • Amgen$198
  • AstraZeneca$129
  • Dynavax Technologies Corporation$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • plus $145 from 4 others

What the payments were for

  • Food & beverage$1,161100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,165 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$27,298
Medicare patients
91
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$50,955
EliquisApixaban45$48,607
OzempicSemaglutide39$38,034
JardianceEmpagliflozin14$19,599
XareltoRivaroxaban21$18,481
RestasisCyclosporine11$6,870
FarxigaDapagliflozin Propanediol11$6,426
SynthroidLevothyroxine Sodium40$3,550
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,156
Atorvastatin Calcium221$2,026
Gabapentin101$1,509
Bupropion XlBupropion Hcl37$1,456
Levothyroxine Sodium161$1,279
Sucralfate12$1,051
Lisinopril154$1,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$292$50,95543 claims
PfizerEliquis$53$48,60745 claims
Novo NordiskOzempic$268$38,03439 claims
AbbVieRestasis, Synthroid$43$10,42051 claims
AstraZenecaFarxiga$129$6,42611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Hebron

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →